From supravalvular to valvular aortic stenosis: are statins contributing to the phenotypic shift in homozygous familial hypercholesterolaemia?
- PMID: 35822615
- DOI: 10.1093/eurheartj/ehac338
From supravalvular to valvular aortic stenosis: are statins contributing to the phenotypic shift in homozygous familial hypercholesterolaemia?
Conflict of interest statement
Conflict of interest: A.B. reports research funding from Amgen Inc., Ionis Pharmaceuticals, Novartis, Pfizer, and Regeneron Pharmaceuticals. M.C. is a member of the steering committee of the Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC); she reports research funding from Regeneron Pharmaceuticals and REGENXBIO; and honoraria from Amryt Pharma.
Comment on
-
Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century.Eur Heart J. 2022 Sep 7;43(34):3227-3239. doi: 10.1093/eurheartj/ehac339. Eur Heart J. 2022. PMID: 35776569
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical